Beyond Air, Inc. (XAIR)
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Beyond Air, Inc.
| Form | Description | Links | |
|---|---|---|---|
| DEFA14A | |||
| DEF 14A | |||
| 13G/A | |||
| PRE 14A | |||
| 4 | |||
| 8-K | |||
| 4 | |||
| 3 | |||
| 13G/A | |||
| 8-K | |||
| EFFECT | |||
| 424B3 | |||
| 8-K | |||
| S-3 | |||
| 13G/A | |||
| 10-Q | |||
| 8-K | |||
| 4 | |||
| 4 | |||
| 8-K | |||
| 13G/A | |||
| 13G | |||
| 8-K | |||
| 8-K | |||
| 10-K |
1-25 of 630 filings
Recent SEC filings with analysis
- 8-KBeyond Air preannounced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026 — its highest quarterly revenue…
- 8-KBeyond Air entered into a formal employment agreement with CEO Robert Goodman on September 23, 2026, formalizing terms after his appointment effective March…